We demonstrated that combination of the number of PRKCD and NCK2 risk genotypes with other known clinicopathologic variables in the same multivariable model significantly improved the prediction accuracy of MSS in CM patients. The gene discussed is NCK2; the disease is cutaneous mastocytosis.